AMN HEALTHCARE SERVICES INC
AMNBusiness Model
source: coverage-next-full ticker: AMN step: 01 title: Business Model & Overview generated: 2026-06-14
Step 01 — Business Model & Overview: AMN Healthcare Services Inc
1. Executive Summary
AMN Healthcare Services Inc (NYSE: AMN) is the largest publicly traded healthcare workforce solutions company in the United States, connecting healthcare facilities with clinical and non-clinical talent while providing technology platforms for workforce management. Founded in 1985 and public since 2001, AMN has grown from a travel nursing agency into a diversified healthcare staffing enterprise with a software overlay. The company operates across three segments: Nurse & Allied Solutions, Physician & Leadership Solutions, and Technology & Workforce Solutions.
As of June 2026, AMN is navigating a multi-year post-COVID normalization: revenue has declined 48% from its FY2022 peak of $5.24B to a run-rate of ~$2.5B (ex-labor disruption events), market cap has fallen to ~$1.19B, and the company carries $767M in net debt. The central investment question is whether the structural nursing and physician shortage floor — combined with the platform moat in ShiftWise VMS and AMN Passport — creates a durable earnings recovery case from current trough multiples. [S1]
2. Value-Chain Layer Map
SUPPLY SIDE AMN PLATFORM DEMAND SIDE
─────────────────────────────────────────────────────────────────────────────────────────
┌──────────────────────┐
Registered Nurses ──────────────► │ AMN Passport App │
Travel Nurses ──────────────────► │ (Clinician Portal) │
Allied Health Professionals ────► │ 200K+ registered │
Locum Physicians ───────────────► │ clinicians │◄─────────────────────┐
International Nurses ───────────► └──────────────────────┘ │
(20% growth YoY 2026) │ │
▼ │
┌──────────────────────┐ ┌───────────────┐
│ ShiftWise VMS │ │ Hospitals │
│ (Vendor Mgmt Sys) │◄───────────►│ Health │
│ Scheduling, analytics│ │ Systems │
└──────────────────────┘ │ (4,600+ │
│ │ clients) │
┌─────────────────┼──────────────┐ └───────────────┘
▼ ▼ ▼
Nurse & Allied Physician & Tech/Workforce
Solutions Leadership Solutions
(61% rev) (26% rev) (14% rev)
Travel nursing Locum tenens SaaS VMS
Per diem Perm search Scheduling
Allied health Exec search Analytics
Revenue model: AMN earns a spread between (a) the bill rate charged to hospitals and (b) the pay rate + benefits paid to clinicians. In technology/VMS, revenue is SaaS licensing + transaction fees. The staffing spread is the core unit economics driver; VMS is higher-margin, recurring.
3. Segment Deep Dive
3.1 Nurse & Allied Solutions (61% of FY2025 revenue = $1,647M)
The largest and most cyclical segment. AMN places registered nurses on short-term (13-week) travel assignments, per diem shifts, and allied health placements (PT, OT, respiratory therapy, imaging). This segment was the primary driver of the COVID supercycle — travel nurse bill rates more than doubled from ~$2,200/week in 2019 to ~$4,000+/week in 2022, then crashed back to ~$2,300/week by 2024-2025.
Key drivers:
- Census levels at hospitals (occupancy → staffing need)
- Travel nurse bill rates (pricing lever)
- Clinician supply in AMN Passport / active pool
- Hospital budget cycles (budget season typically Q4 → Q1 locking rates)
- Strike contingency events (episodic, high-margin, non-repeating)
3.2 Physician & Leadership Solutions (26% of FY2025 revenue = $696M)
Locum tenens (temporary physician staffing) across all specialties, permanent physician and executive search, and interim healthcare leadership. This segment is more stable than travel nursing — physician shortages are structural and less sensitive to short-term hospital budget cuts. Includes the MSDR acquisition (Nov 2023, direct-hire physician staffing) and legacy Staff Care brand.
Key drivers:
- Physician burnout rates and retirement velocity
- Specialty shortages (primary care, psychiatry, anesthesiology)
- Rural and underserved facility gaps
- Hospital M&A (consolidated systems buy more services)
3.3 Technology & Workforce Solutions (14% of FY2025 revenue = $387M)
The highest-quality, most durable segment. ShiftWise Flex is AMN's VMS (Vendor Management System) — the software layer hospitals use to manage all contingent labor, regardless of which staffing agency fills the role. AMN Passport (200K+ registered clinicians) is a direct-hire / self-scheduling mobile platform. Also includes WorkWise (internal scheduling), Televate (workforce analytics), and the language services subsidiary.
Note: AMN sold SmartSquare (scheduling software) in July 2025 for $39M, recognizing the gain and narrowing focus to the talent acquisition platform. [S4]
Key drivers:
- VMS adoption penetration (hospitals converting from manual processes)
- AMN Passport clinician self-scheduling growth
- Technology contract renewals (multi-year, stickier than staffing contracts)
- Cross-sell between staffing and technology products
4. Customer Concentration & Mix
| Customer Segment | Approx. % of Revenue |
|---|---|
| Kaiser Permanente (largest) | ~16% (FY2024) |
| Top 10 customers | ~35-40% (est.) |
| Long-term care / SNFs | ~5-10% |
| Ambulatory / outpatient | ~5-10% |
| Technology-only clients | Growing |
[S3] Kaiser concentration represents meaningful single-customer risk. A contract renegotiation or termination would materially impact revenue.
5. Revenue Model & Unit Economics
Staffing (Nurse & Allied, Physician):
- Bill rate to hospital: $2,200–$2,500/week for travel nurse (normalized 2025)
- Pay + benefits to clinician: ~70-72% of bill rate (gross margin ~28-30%)
- Assignment length: 13-week standard; may extend
- Placement volume drives top-line; bill rate × volume = revenue
Technology (VMS):
- Subscription + transaction fee model
- Gross margin: ~45-55% (much higher than staffing)
- Multi-year contracts with hospital systems
- Revenue recognition: ratably over contract term
Overall blended gross margin: ~28-30% (FY2024-2025, down from ~33% at FY2022 peak)
6. Strategic Position
AMN's strategic differentiation rests on three interlocking claims:
- Scale in supply: 200K+ clinicians in AMN Passport creates a supply advantage for rapid, large-scale placements (critical for strike events, surge staffing)
- Technology lock-in: ShiftWise VMS embedded in hospital workflows → switching cost moat
- Breadth of solutions: 20+ workforce solutions across nursing, physicians, allied, leadership, and technology → single-vendor relationship reduces hospital administrative burden
Recent strategic actions: De-leveraging focus (paid $285M of debt in FY2025), SmartSquare divestiture (July 2025), international nurse pipeline expansion (+20% YoY in 2026), management emphasis on "total talent platform" framing.
7. Competitive Context (Preview)
AMN has been surpassed in revenue scale by Aya Healthcare (private, est. $6.9B revenue), CHG Healthcare (private, $2.8B), and Jackson Healthcare (private, ~$2.5B) — making AMN the largest publicly traded healthcare staffing company but #4 overall. This competitive repositioning is a significant thesis risk. [S8]
Source Index
| ID | Source | Type | Retrieved |
|---|---|---|---|
| S1 | StockAnalysis.com/stocks/amn — overview | Web | 2026-06-14 |
| S2 | SEC XBRL companyfacts (CIK 0001142750) | API | 2026-06-14 |
| S3 | AMN 10-K FY2024 (business, segments, risk factors) | Filing | 2026-06-14 |
| S4 | AMN investor presentation 2025 / earnings PR | Web | 2026-06-14 |
| S5 | SEC DEF 14A 2026 proxy | Filing | 2026-06-14 |
| S6 | AMN 10-K FY2025 (segments, strategy) | Filing | 2026-06-14 |
| S7 | Industry competitive landscape research | Web | 2026-06-14 |
| S8 | Tavily web search: AMN competitive position 2025-2026 | Web | 2026-06-14 |
Financial Snapshot
source: coverage-next-full ticker: AMN step: 04 title: Financial Quality & Adversarial Sweep generated: 2026-06-14
Step 04 — Financial Quality & Adversarial Sweep: AMN Healthcare Services Inc
1. Statement Quality Assessment
Revenue Recognition
AMN recognizes staffing revenue as services are rendered (time-and-materials for shifts/assignments). Technology/VMS revenue is recognized ratably over the contract term for subscriptions, or on a fee-per-transaction basis for marketplace placements. Revenue recognition follows ASC 606 (adopted 2018). [S1]
Quality assessment: CLEAN. Staffing revenue recognition is straightforward — no material cutoff or acceleration concerns. Technology revenue ratable recognition is appropriate and conservative.
Red flags: None identified in revenue recognition. Prior year restatements: none in public record.
Earnings Quality Adjustments
| Item | Amount | Notes |
|---|---|---|
| Goodwill impairment (FY2024) | ~$182M | Non-cash; excluded from adjusted EBITDA |
| Goodwill impairment (FY2025 est.) | ~$150M | Non-cash; excludes from adjusted earnings |
| Amortization of intangibles | ~$85M/yr | Non-cash; from acquisition accounting |
| Stock-based compensation | ~$45M/yr | Non-cash dilution; legitimate operating cost |
| Restructuring charges | ~$20-30M | FY2024-2025 workforce reductions |
| SmartSquare gain (July 2025) | +$39M | One-time gain; excludes from adjusted |
Adjusted vs. GAAP disconnect: GAAP net income has been negative for FY2024 and FY2025 primarily due to goodwill impairment charges. Adjusted EBITDA (~$280-320M for FY2025) gives a much more favorable picture. The gap between GAAP and adjusted is larger than typical for a staffing company — investors must understand the impairment story.
FCF vs. GAAP earnings: FCF has remained positive throughout the decline ($219M–$578M range over FY2020-FY2022 peak, still positive in FY2024-2025). This is the key positive quality signal: even with GAAP losses from impairment, the business generates real cash. [S2]
Cash Flow Quality
| Metric | FY2022 (peak) | FY2023 | FY2024 | FY2025E |
|---|---|---|---|---|
| Operating CF | ~$650M | ~$390M | ~$275M | ~$200M |
| CapEx | ~$72M | ~$80M | ~$60M | ~$50M |
| FCF | ~$578M | ~$310M | ~$215M | ~$150M |
| FCF Margin | ~11% | ~8.1% | ~7.2% | ~5.5% |
[S2] FCF figures from StockAnalysis.com cash flow data and XBRL. FY2025 estimated.
Working capital dynamics: Staffing companies carry accounts receivable (typically 45-60 days DSO). AR has declined commensurate with revenue — no signs of channel stuffing or extended collections.
CapEx intensity: Very low (2-3% of revenue) — confirms capital-light staffing model. Technology capex is the largest component (platform development, capitalized software). CapEx trending down with revenue.
2. Balance Sheet Quality
Goodwill & Intangibles
| Line | FY2023 | FY2024 | FY2025E |
|---|---|---|---|
| Goodwill | ~$958M | ~$756M | ~$756M |
| Intangibles, net | ~$450M | ~$350M | ~$250M |
| Total goodwill + intangibles | ~$1,408M | ~$1,106M | ~$1,006M |
| Total equity | ~$1,100M | ~$850M | ~$750M |
| Tangible book value | NEGATIVE | NEGATIVE | NEGATIVE |
[S2][S3] Goodwill and intangibles data from XBRL and StockAnalysis.com.
Goodwill risk: Remaining goodwill of ~$756M represents ~63% of current market cap ($1.19B). Further impairment is possible if Nurse & Allied Solutions or Technology segment cash flow projections deteriorate. The $182M FY2024 + $150M FY2025 impairment history suggests management has been slow to write down acquisition premiums. This is a red flag for acquisition quality (see Step 07). [S3]
Negative tangible book value: AMN has negative tangible book equity ($756M goodwill + ~$250M intangibles > total stockholders' equity). This is common in acquisition-heavy staffing/services companies but means the stock cannot be valued on book value — EV/EBITDA and FCF are the appropriate anchors.
3. Debt & Liquidity Quality
Debt Structure
| Instrument | Amount (FY2025E) | Rate | Maturity |
|---|---|---|---|
| Revolving credit facility | Drawn TBD | SOFR + ~175bps | ~2027 |
| Term loan | ~$400M | SOFR + ~175bps | ~2027-2028 |
| Senior secured notes | ~$300M | Fixed 4.625% | ~2027 |
| Total gross debt | ~$870M | ||
| Less: cash | ~$100M | ||
| Net debt | ~$770M |
[S4] Estimates based on investor presentation disclosure and Fitch 'BB' stable rating (confirmed June 2026).
Leverage trajectory:
- FY2023: ~4.5x net leverage (peak debt from Connetics/MSDR acquisitions)
- FY2024: ~4.0x
- FY2025: ~3.3x (paid $285M of debt)
- FY2026E: ~2.5-3.0x (implied by guidance + FCF)
Maturity wall concern: Multiple tranches mature in 2027-2028. AMN needs to refinance ~$700M+ of debt within 2 years. With Fitch 'BB' stable, refinancing is feasible but at higher rates than the current locked-in rate (Fed funds environment). Interest expense is ~$50-55M/year. [S4]
Covenant risk: Credit agreement likely contains leverage-based financial covenants. If adjusted EBITDA declines further, covenant headroom may compress. Investor presentation noted focus on debt reduction as a priority — consistent with management awareness of covenant risk.
4. Adversarial Research Sweep
4.1 Short Seller / Critical Research
No significant short seller reports identified in public record for AMN. Short interest (as of May 2026) is moderate (~5-8% of float, estimated from consensus data). The stock has already declined ~75%+ from its 2022 peak, limiting short-side upside from existing bears.
Critical analyst notes identified:
- Several analysts (Hold rating, $25-26 price target vs. current $30.80) argue the stock has re-rated ahead of fundamentals given Q1 2026 strike distortion
- Bears note: Q2 2026 guidance of $620-635M implies annualized revenue of ~$2.5B — AMN at $30.80 trades at ~$1.19B market cap, or ~0.47x revenue. Bears argue this is still fair value, not cheap, given leverage and competitive erosion. [S5]
- Key bear concern: no insider buying despite 75% stock decline from peak (see proxy/insider data)
4.2 Legal, Regulatory & Litigation
No material litigation identified. Review of 10-K risk factors:
- Standard employment law risks (wage/hour claims, discrimination)
- Healthcare staffing compliance (state licensure, Joint Commission standards)
- Immigration and visa-related risks for international nurse program
- No identified class action lawsuits, SEC investigations, or material regulatory sanctions
FCPA/International: Limited international operations (primarily sourcing). Low FCPA risk.
4.3 Accounting Red Flags Checklist
| Flag | Status | Notes |
|---|---|---|
| Revenue acceleration vs. cash flow | CLEAR | FCF positive, no divergence trend |
| Channel stuffing / deferred revenue | CLEAR | Services business; not applicable |
| Goodwill impairment timing | WATCH | FY2024-2025 impairments; timing questions (why not earlier?) |
| Related-party transactions | CLEAR | No unusual RPT identified in proxy |
| Auditor changes | CLEAR | KPMG consistent; no auditor change |
| Going concern language | CLEAR | No going concern in FY2025 10-K |
| Pension/off-balance obligations | LOW | Minimal pension; operating leases disclosed per ASC 842 |
| Revenue concentration | WATCH | Kaiser 16% concentration — disclosed but material |
4.4 SEC Filing Review Notes
No unusual SEC comment letters in recent years. Standard 10-K and 10-Q filings with consistent accounting policies. Segment reporting consistent year-over-year. [S1]
5. Financial Quality Summary
| Dimension | Rating | Notes |
|---|---|---|
| Revenue quality | HIGH | Simple services model; clean recognition |
| Earnings quality | MEDIUM | GAAP distorted by impairment; adj EBITDA cleaner |
| Cash flow quality | HIGH | FCF positive throughout decline; real cash business |
| Balance sheet quality | MEDIUM | Negative tangible book; goodwill risk; manageable leverage |
| Accounting transparency | HIGH | No restatements; clear segmentation; consistent policies |
| Governance/audit | MEDIUM-HIGH | No red flags; elevated CEO comp vs. stock performance |
| Litigation risk | LOW | No material litigation |
| Overall | MEDIUM-HIGH | Good cash business, goodwill/leverage are the watchitems |
Source Index
| ID | Source | Type | Retrieved |
|---|---|---|---|
| S1 | AMN 10-K FY2024/FY2025 — revenue recognition, risk factors | Filing | 2026-06-14 |
| S2 | StockAnalysis.com — cash flow, balance sheet | Web | 2026-06-14 |
| S3 | SEC XBRL — goodwill, intangibles time series | API | 2026-06-14 |
| S4 | Investor presentation 2025 — debt reduction, leverage | Web | 2026-06-14 |
| S5 | Consensus.md — analyst ratings, bear concerns | Web | 2026-06-14 |
| S6 | SEC DEF 14A — governance, auditor | Filing | 2026-06-14 |
Recent Catalysts
source: coverage-next-full ticker: AMN step: 12 title: Bull vs. Bear — Analyst Debate generated: 2026-06-14
Step 12 — Bull vs. Bear: AMN Healthcare Services Inc
Note: This step was prepared without earnings call transcripts (coverage-next-full path). The analyst debate is reconstructed from consensus notes, press releases, investor presentations, and recent news. Specific sell-side research notes are cited where available.
1. The Central Debate
The AMN debate is fundamentally a disagreement about post-COVID equilibrium revenue and the strategic value of the technology platform vs. competitive share loss. Bulls see a deeply discounted "quality at a trough" situation; bears see structural competitive deterioration with leverage risk.
Current valuation context: Stock at $30.80/share, $1.19B market cap, 38.8M diluted shares. 9 analyst coverage: 2 Strong Buy / 1 Buy / 5 Hold / 1 Sell. Average price target: $25.29 (stock trades 22% above average analyst target). [S1]
The paradox: The stock has already re-rated significantly above analyst targets. This suggests the market is pricing in a recovery scenario while most analysts are cautious. Either (a) the market is right and the recovery is underway, or (b) Q1 2026's strike distortion has inflated investor optimism and the stock will re-correct toward $22-26 as organic results normalize.
2. Bull Case Framework
Primary Bull Arguments (from press releases, investor presentations, consensus notes)
Bull Argument 1: Trough valuation with structural demand floor Healthcare staffing has a structural demand floor from the nursing shortage (193K+ annual RN openings through 2032). Travel nurse volumes have stabilized and may be in early recovery. At ~5-6x FCF (FY2026E) and ~$1.19B EV vs. ~$300M normalized EBITDA (~4x EV/EBITDA), AMN appears deeply discounted relative to its earnings power. [S2]
Bull Argument 2: ShiftWise VMS creates durable competitive moat ShiftWise is the market-leading VMS in healthcare. The 2026 Joint Commission NPSG 12 compliance requirement (staffing compliance documentation) is a direct tailwind for ShiftWise adoption. FTC's blocking of the Aya-CCRN merger (Dec 2025) implicitly validates ShiftWise's strategic value. The technology platform creates predictable, recurring revenue at 45-55% gross margins vs. staffing's 28-30%. [S3]
Bull Argument 3: De-leveraging creates capital return optionality AMN paid $285M of debt in FY2025. At ~$150-200M FCF/year and declining leverage (3.3x → target ~2.0x), the company can be substantially de-levered by 2027-2028. At 2.0x leverage, the capital structure provides flexibility for buybacks at current depressed prices or strategic M&A. The buybacks at ~$81/share average in FY2022-2023 look terrible; buying at $30/share would be value-accretive. [S4]
Bull Argument 4: International nurse pipeline is a structural supply advantage Connetics (acquired 2022) provides AMN with a direct pipeline of Philippines-sourced international nurses. International nurse placements growing +20% YoY in 2026. International nurses are lower-cost to source vs. domestic travel nurses and create a differentiated supply that competitors cannot replicate quickly. [S3]
Bull Argument 5: Strike staffing validates AMN as system-critical provider Q1 2026's $722M in strike-staffing revenue (delivered in ~3 months) demonstrates AMN's unique capability to mobilize 5,000+ clinicians for emergency situations. Only a handful of staffing companies globally can do this. Kaiser's reliance on AMN during its major strike reinforces the depth and importance of this relationship. Strike events are episodic but recurring (labor relations in healthcare remain contentious), creating an optionality element in the earnings profile. [S1]
3. Bear Case Framework
Primary Bear Arguments
Bear Argument 1: Structural market share erosion — Aya has lapped AMN and is not stopping Aya Healthcare went from roughly AMN-equivalent size in 2020 to $6.9B (2.3x AMN) by 2024. This is not cyclical underperformance — AMN has permanently lost market share to a better-capitalized, private competitor. Aya's private funding allows it to subsidize clinician pay and hospital relationships more aggressively than a public company under pressure. Without a leveraged buyout or financial restructuring, AMN cannot close the gap. [S4]
Bear Argument 2: Q2 2026 guidance ($620-635M) reveals the organic business is not recovering Q1 2026's $1.38B revenue beats was driven by $722M of strike staffing — a one-time event. Strip that out and the organic business was ~$658M in Q1 2026. Q2 2026 guide is $620-635M — slightly lower than Q1 organic. There is no acceleration in the underlying business; it is flat to slightly declining. The stock at $30.80 (22% above average analyst target) implies a recovery premium that is not yet visible in results. [S1]
Bear Argument 3: Leverage + maturity wall = constrained flexibility 3.3x net leverage with a ~$700M+ debt maturity wall in 2027-2028 creates refinancing risk. If adjusted EBITDA stays at $280-300M (low end of range), net leverage remains 2.5-3.0x at refinancing — not terrible but not clean. Refinancing at SOFR+ rates that are 200bps higher than embedded rates adds ~$14M in annual interest expense, compressing FCF. Management's stated priority of debt repayment over capital return means no buybacks or dividends for 2-3 years. [S4]
Bear Argument 4: No insider buying despite 75% stock decline from peak Not a single director or officer has made an open-market purchase in 2024-2025 despite the stock declining from $120+ to $15 at the trough. RSU vesting is mandatory; open-market buying is optional and revealing. The absence of insider conviction at any price between $15 and $30 is a warning signal that insiders who know the business best are not personally betting on the recovery. [S5]
Bear Argument 5: Goodwill impairment history signals M&A value destruction AMN has impaired $332M+ of goodwill in FY2024-2025 alone. The acquisitions that generated this goodwill (MSDR at ~$360M, various others) have not created demonstrable shareholder value. The remaining $756M of goodwill represents ongoing impairment risk — any further deterioration in Nurse & Allied or Physician segment trajectories would trigger additional write-downs, further eroding the GAAP balance sheet. [S6]
4. Key Swing Variables
| Variable | Bull Case | Bear Case |
|---|---|---|
| Organic revenue Q2-Q4 2026 | $650M+/quarter (recovery) | $580-620M (declining) |
| FY2027 revenue trajectory | $3.0-3.5B | $2.3-2.6B |
| ShiftWise contract wins | 5+ new major contracts | Flat/losing to Symplr |
| Aya competitive pressure | Stabilizes (market too large) | Continues taking share |
| Kaiser renewal | Multi-year extension | Renegotiation → lower rates |
| Leverage by YE2026 | <2.5x | 3.0x+ (EBITDA disappointment) |
| Insider activity | Purchases at sub-$30 | Continued absence of purchases |
5. Debate Synthesis
The core disagreement: Is Q2 2026's guidance ($620-635M) the floor, or could volumes deteriorate further?
- Bull view: Q4 2024 ($633M) was the absolute trough; the trend since is gradually improving; Q2 2026 represents seasonal softness post-strike; H2 2026 should show acceleration as hospitals refill from depleted internal float pools.
- Bear view: The organic run-rate has been $600-650M/quarter for 6 quarters (post-trough) with minimal improvement; hospital float pools are now fully staffed; the equilibrium organic business is ~$2.4-2.6B/year, not the $2.9-3.5B that bulls project.
The stock at $30.80 with a $25.29 analyst consensus target suggests the market is pricing in the recovery scenario. At current prices, the risk/reward appears asymmetric toward the downside unless the organic business can demonstrate acceleration above $650M/quarter by Q3-Q4 2026.
Bull Case — 3 Bullets
Structural demand floor: The nursing shortage (193K+ annual RN openings) and physician shortage provide a durable floor for healthcare staffing demand that has not normalized below pre-COVID levels; at ~5-6x FCF trough multiple, AMN is priced for permanent decline in a structurally growing market.
ShiftWise VMS moat + NPSG 12 tailwind: ShiftWise is the entrenched market-leading healthcare VMS with genuine hospital switching costs; the 2026 Joint Commission staffing compliance mandate is a direct catalyst for VMS adoption, and the FTC's Aya-CCRN antitrust block validates ShiftWise's strategic scarcity as a neutral infrastructure layer.
De-leveraging unlocks capital optionality: $285M paid in FY2025 with ~$150-200M FCF/year targets 2.0x leverage by FY2027; at that point, AMN can buy back stock at $30 vs. prior buybacks at $81, creating meaningful per-share value for remaining holders.
Bear Case — 3 Bullets
Structural market share loss to Aya Healthcare: Aya now generates 2.3x AMN's revenue with private capital backing that AMN's public-company constraints cannot match; the share loss pattern (AMN from #1 to #4 in 4 years) has not stabilized, and there is no visible mechanism for AMN to recapture share without the M&A capacity it has ceded to de-leveraging.
Organic business not recovering — Q1 2026 was a mirage: The Q1 2026 beat was $722M of episodic strike-staffing revenue; strip it out and the organic run-rate is $658M (flat-to-declining vs. Q4 2025's organic
$648M); Q2 2026 guidance of $620-635M confirms the underlying business is range-bound at $600-650M/quarter ($2.4-2.6B annualized), implying the stock at $30.80 is trading at 14-16x forward FCF — not cheap.No insider conviction at any price: Despite a 75%+ stock decline from peak, zero insiders have made open-market purchases at any price between $15 and $31; insiders with $2-10M annual compensation could demonstrate conviction at minimal personal risk — the persistent absence of buying across 2+ years of low prices is the most bearish single data point available.
Source Index
| ID | Source | Type | Retrieved |
|---|---|---|---|
| S1 | Consensus.md — analyst ratings, targets, Q1 2026 actuals | Web | 2026-06-14 |
| S2 | SEC XBRL — FCF, valuation inputs | API | 2026-06-14 |
| S3 | Investor presentation — technology strategy, NPSG 12 | Web | 2026-06-14 |
| S4 | Industry competitive landscape — Aya, leverage analysis | Web | 2026-06-14 |
| S5 | SEC Form 4 filings — insider activity | Filing | 2026-06-14 |
| S6 | StockAnalysis.com / XBRL — goodwill impairment history | Web/API | 2026-06-14 |
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.